Management of amiodarone-induced thyrotoxicosis

Swiss Medical Weekly

Volumn 133, Issue 43-44, 2003, Pages 579-585

  Rajeswaran, Chinnadorai ^a,b   Shelton, Rhidian John ^a   Gilbey, Stephen George ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Amiodarone; Corticosteroids; Thionarnides; Thyroid function test; Thyrotoxicosis

Indexed keywords

ALCOHOL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHYROID AGENT; CARBIMAZOLE; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 6; IOPANOIC ACID; LIOTHYRONINE; LITHIUM; PERCHLORATE; PREDNISOLONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; THIAMAZOLE; THIONAMIDE; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN; THYROXINE;

APLASTIC ANEMIA; CLINICAL ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; FOLLOW UP; GRAVES DISEASE; HEART ARRHYTHMIA; HUMAN; HYPOTHYROIDISM; PLASMAPHERESIS; PREVALENCE; REVIEW; THYROID DISEASE; THYROID FUNCTION TEST; THYROTOXICOSIS; TOXIC GOITER; TREATMENT INDICATION;

EID: 0347513049     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Withering W. An account of the Foxglove and some of its medical uses with practical remarks on dropsy and other diseases. London; 1785.
2. Ostranderld JR, Brandt RL, Kjelsberg MO, Epstein FH. Electrocardiographic findings among the adult population of a total natural community, Tecumseh, Michigan. Circulation 1965;31:888-9.
3. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.
4. Podrid PJ. Amiodarone: re-evaluation of an old drug. Ann Intern Med 1995;122:689-700.
5. Wiersinga WM. Amiodarone and the thyroid. In: Weetman AR, Grossman A. Pharmacotherapeutics of the thyroid gland. Springer Verlag, Berlin 1997; pp. 225-87.
6. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med 2000;160:1741-8.
7. Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
8. Rao RH, McReady VR, Spathis G. Iodine kinetic studies during amiodarone treatment. J Clin Endocinol Metab 1986;62:563-7.
9. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clinical Pharmacokinetics 1984;9:136-56.
10. Iervasi G, Clerico A, Bonini R, Manfredi C Berti, et al. Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia. The Journal of Clinical Endocrinology & Metabolism 1997;82:275-80.
11. Badmanaban B, Mulholland K, Mazin AI. Sarsam: Amiodarone Induced Rebound Acute Thyrotoxicosis After CABG. The Internet Journal of Thoracic and Cardiovascular Surgery 2003;5.
12. Nademanee K, Piwonka RW, Singh BN, Hershman JM. Amiodarone and thyroid function. Prog Cardiovasc Dis 1989;31:427-37.
13. Trip MD, Wiersinga WM, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991:53-7.
14. Martino E, Safran M, Aghini-Lomardi F, Rajatanavin R, Lenziardi M, et al. Enviromental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28-34.
15. Martino E, Aghini-Lomardi F, Mariotti S, Bartalena L, Lenziardi M, Ceccarelli C, et al. Amiodarone induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol (Oxf) 1987;26:227-37.
16. Braverman LE, Ingbar SH, Vagenakis AG, Adams L, Maaloof F. Enhanced susceptibility to iodide myxoedema in patients with Hashimoto's disease. J Clin Endocrinol Metab 1971;32:515-21.
17. Braverman LE. Diseases of the Thyroid. Humana Press. Totowa, New Jersey; 1997.
18. DeGroot LJ, Jameson JL. Endocrinology. Volume 2. 4th Ed. WB. Saunders, London, 2001.
19. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effect of low dose amiodarone: a meta-analysis. J Am Col Cardiol 1997;30(3):791-8.
20. Martino E, Aghini-Lombardi F, Lippi F, Baschieri L, Safran M, Lewis E. Twenty-Four Hour Radioactive Iodine Uptake in 35 Patients with Amiodarone Associated Thyrotoxicosis. J Nuclear Med 1985;26:1402-7.
21. Harjai KJ, Licata AA. Amiodarone induced hyperthyroidism: a case series and brief review of literature. Pacing Clin Electrophysiology 1996;19:1548-54.
22. Bogazzi F, Bartalena L, Gasperi M, Braverman LE, Martino E. The various effects of amiodarone on thyroid function. Thyroid 2001;11:511-9.
23. Martino E, Bartalena L, Bogazzi F, et al. The Effects of Amiodarone on the Thyroid. Endocrine Reviews 2001;22:240-54.
24. Newman CM, Price A, Davies DW, Gray TA, Weetman AP. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79:121-7.
25. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardini F, Braverman LE, Martino El. Serum Interleukin-6 in Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol & Metabolism 1994;78:423-7.
26. Meurisse M, Gollogly L, Degauque C, Fumal I, Defechereux T, Hamoir E. Iatrogenic Thyrotoxicosis: Causal Circumstances, Pathophysiology, and Principles of Treatment-Review of Literature. World of Surgery 2000;24:1377-85.
27. Osman F, Franklyn JA, Sheppard MC, Gammage MD. Successful treatment of amiodarone induced thyrotoxicosis. Circulation 2002;105:1275-81.
28. Brennan MD, Erickson DZ, Carney JA, et al. Non-goitrous (type I) Amiodarone-associated Thyrotoxicosis - Evidence of follicular disruption in-vitro and in-vivo. Thyroid 1995;5:177-83.
29. Bogazzi F, Bartalena L, Brogioni S, Maxxeo S, Vitti P, Burelli A, et al. Colour flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997;7:541-45.
30. Moolman JA. Thyroid hormone and the heart. Cardiovascular J of South Africa 2002;13:159-63.
31. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of thyroid in amiodarone-induced thyrotoxicosis. Am J Surg Pathol 1987;11:197-204.
32. Leger FA, Beaulieu J, Malinsky M, Chomette G, Savoie J. Therapeutic aspects of iodine-induced thyrotoxicosis. Ann Endocrinol 1977;38:86.
33. Roti E, Minelli R, Gardini E, Bianconi L, Braverman LE. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone: a possible consequence of a destructive process in the thyroid. Arc Intern Med 1993;153:886-92.
34. Leger AF, Massin JP, Laurent MF, et al. Iodine induced thryotoxicosis: analysis of eighty-five consecutive cases. Eur Jr Clin Invest 1984;14:449-55.
35. Brennan MD, Van Heerden JA, Carney JA. Amiodarone Associated Thyrotoxicosis (AAT): experience with surgical management. Surgery. 1987;102:1062-7.
36. Bartalena L, Bogazi F, Martino E, et al. Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge. Clin Endocrinol 2002;56:23-4.
37. Daniels GH. Amiodarone-Induced Thyrotoxicosis. J Clin Endocrinol & Metabolism 2001;86:3-8.
38. Van de Wiele C, Osmananaolu K, Van Laere K, Kaufman JM, Dierckx RA. 201Ti Scintigraphy does not allow visualization of the thyroid in euthyroid and hyperthyroid patients treated with amiodarone. Nuclear Med Commun 1997;18:513-6.
39. Wolf J. Perchlorate and the thyroid gland. Pharmacol Rev 1998;50:89-105.
40. Lazarus JH, Obuobie K. Thyroid disorders - an update. Postgrad Med J 2000;76:529-36.
41. Eaton SM, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour flow Doppler sonography. Clin Endocrinol 2002;56:33-8.
42. Amico JA, Richardson V, Alpert B, et al. Clinical and chemical assessment of thyroid function during therapy with amiodarone. Arch Intern Med 1984;144:487-90.
43. Franklyn JA, Davis JR, Gammage RL, et al. Amiodarone and thyroid hormone action. Clin Endocrinol 1985;22:257-64.
44. Reichert LJ, de Roov HA. Treatment of amiodarone-induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. BMJ 1989;298:1547-8.
45. Bartaleno L, Brogioni S, Grasso L, et al. Treatment of amiodarone induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol & Metabolism 1996;81:2930-3.
46. Nakajima K, Yamazaki K, Yamada E, Kanaji Y, Kosaka S, Sato K, Takano K. Amiodarone stimulates interleukin-6 production in cultured human thyrocytes exerting cytotoxic effects on thyroid follicles in suspension cultures. Thyroid 2001;11:101-9.
47. Martino E, Aghini-Lombardi F, Mariotti S, et al. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 1987;26:158-71.
48. Brosolle C, Ducottet X, Martin C, et al. Rapid effectiveness of prednisolone and thionamides combined therapy in severe amiodarone-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. J Endocrinol Invest 1989;12:37-42.
49. Claxton S, Sinha SN, Donovan S, Greenaway TM, Hoffman L, Loughhead M, Burgess JR. Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy. Australian & New Zealand Journal of Surgery 2000;70:174-8.
50. Hamoir E, Meurisse M, Defechereux T, Joris J, Vivario J, Vivarioj, Hennen G. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective? World Journal of Surgery 1998;22:537-42; discussion 542-3.
51. Meurisse M, Hamoir E, D'Silva M, Joris J, Hennen G. Amiodarone-induced thyrotoxicosis: is there a place for surgery? World Journal of Surgery 1993;17:622-6.
52. Farwell AP, Abend SL, Huang SK, Patwardhan NA, Braverman LE. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990;263:1526-8.
53. Brennan MD, Van Heerden JA, Carney JA. Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management. Surgery 1987;102:1062-7.
54. Williams M, Lo Gerfo P. Thyroidectomy using local anaesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 2002;12:523-5.
55. Bogazzi F, Aghini-Lombardi F, Cosci C, Lupi I, Santini F, Tanda ML, et al. Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. J Endocrinol Invest 2002;25:176-80.
56. Bogazzi F, Bartalena L, Cosci C, Brogioni S, Dell'Unto E, Grasso L, et al. Treatment of Type II Amiodarone-Induced Thyrotoxicosis by Either Iopanoic Acid or Glucocorticoids: A Prospective, Randomized Study. J Clin Endocrinol & Metabolism 2003;88:1999-2002.
57. Braga M, Cooper DS. Oral cholecystographic agents and the thyroid. J Clin Endocrinol & Metabolism 2001;86:1853-60.
58. Aghini-Lombardi F, Mariotti S, Fosella PV, Grasso L, Pinchera A, Braverman LE, et al. Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole. J Endocrinol Invest 1993;16:823-6.
59. Uzzan B, Pussard E, Leon A, Bekhechi D, Krivitzky A, Modigliani E, et al. The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone induced thyrotoxicosis. Br J Clin Pharmacol 1991;31:371-2.
60. Samaras K, Marel GM. Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted amiodarone-induced thyroiditis. Clin Endocrinol 1996;45:365-8.
61. Dickstein G, Shechner C, Adawi F, Kaplan J, Baron E, Ish-Shalom S. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997;102(5):454-8.
62. Monzani F, Del Guerra P, Caraccio N, Casolaro A, Pucci E, Franchi F. Percutaneous ethanol injection therapy of autonomous nodule and amiodarone-induced thyrotoxicosis. Thyroidology 1994;6(3):99-102.